Oppenheimer initiated coverage of Monopar Therapeutics (MNPR) with an Outperform rating and $77 price target The company acquired ALXN1840 from AstraZeneca in October 2024 “with the goal of bringing it back to life,” the analyst tells investors in a research note. The firm believes Monopar has a “compelling opportunity” to show regulators that the data-to-date support ALXN1840’s differentiated mechanism by addressing flaws in the previous study design and analysis around copper excretion. It believes ALXN1840 can address limitations with standard of care in Wilson disease patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics initiated with an Outperform at Oppenheimer
- Monopar Therapeutics initiated with a Strong Buy at Raymond James
- Monopar Therapeutics files $300M mixed securities shelf
- Monopar Therapeutics assumed with a Buy at H.C. Wainwright
- Monopar Therapeutics management to meet with Cantor Fitzgerald